Tagged with Generic

Morocco Three years on from his last PharmaBoardroom interview, Karim Lahlou highlights the evolution of Moroccan pharma manufacturer Iberma as it expands its activities from solely in-licensing to developing and selling its own products, growing its global partnership base, and looking to penetrate international markets while leveraging the growing reputation of…

Morocco Recently rebranded from its former name, AMIP, the Moroccan Federation of Pharmaceutical Industry and Innovation (FMIIP) represents the local manufacturers operating in Morocco, which hold a domestic market share of 75 percent. Executive Director Layla Laassel Sentissi highlights some of the key trends in the Moroccan pharma market today, how…

Global Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to ensure greater access to their essential products. Martinez argues that for people living in low-and middle-income countries (LMICs), generic and…

UAE Less than two years into position as CEO of MENA-wide pharma and consumer health player Dar Al Dawa, Khaled Harb looks back on what has already been achieved and the ambitious strategy he has put in place for the short-, medium-, and long-term. Harb also outlines some of the key…

Belgium Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some of the key trends at play in the Belgian generics market, and his hopes for how a more sustainable healthcare…

Belgium Medaxes – the Belgian industry association for companies producing generic and biosimilar medicines, as well as other off-patent medicines and self-care products – welcomed a new CEO in 2022, Jasmien Coenen. Here, Coenen describes how the growing awareness of generics and biosimilars in Belgium is not yet translating into a…

UAE Newly promoted to manage Aspen’s Middle East and Europe region, Daniel Vella Friggieri outlines the rationale behind the company’s strategic reconfiguration, how the South-Africa headquartered firm is looking to expand its portfolio in the region via partnerships, and the importance of flexibility and out-of-the-box thinking in driving growth.   The…

Belgium Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far in the Belgian market, and what he sees as Celltrion’s role as driving savings and positive change in the country’s…

Belgium Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus on the hospital generics niche, and his hopes for continuing to meet unmet patient need in Belgium in the coming…

Belgium Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV, and his goals around making an impact for patients in Benelux over the coming years.   If you see the…

UAE Tarek Thaher of MS Pharma, a leading generics firm in the Middle East and Africa, describes the benefits of manufacturing localisation in the UAE, his excitement about the firm’s growth trajectory based on a host of upcoming product launches, and its moves into the biosimilars space.   All in all,…

UAE Tabuk Pharmaceuticals is a Saudi success story, now established as one of the GCC region’s leading private pharmaceutical companies. Gulf Manager Ossama Salah Ramadan explains what attracted him to the firm, his current strategic objectives in line with the company’s global growth goals, and some of the key local trends…